XPRIZE Foundation Launches $101 Million Competition Advancing Anti-Aging Research

The US XPRIZE Foundation has recently announced an exciting competition with a prize pool of $101 million. The competition aims to reward researchers who can develop innovative solutions to reverse or slow down the aging process on the muscles, cognition, and immune system of older adults.

Established in 1995, the XPRIZE Foundation is a non-profit organization dedicated to education and recognition. It inspires individuals, companies, and organizations worldwide to tackle some of the most significant challenges by organizing large-scale competitions with clear and objective goals.

Over the years, the foundation has successfully organized 27 competitions in diverse fields such as space exploration, firefighting, and energy conservation. These competitions have awarded over $300 million in total, with an average prize of approximately $10 million per competition.

The previous Carbon Removal Competition in 2021 offered a total prize of $100 million. The latest competition, named XPRIZE Healthy Lifespan, is generously sponsored by Chip Wilson, the founder of a Canadian sportswear company, and the Hevolution Foundation, a Saudi non-profit organization focused on anti-aging research. The total prize money for this competition exceeds $100 million, and the specific amount awarded to researchers will depend on their achievements.

The primary objective of the competition is to enhance the physical and cognitive functions of older adults, including muscle flexibility, strength, and memory. Additionally, it aims to improve the immune systems of individuals aged 65 to 80 and explore strategies to combat aging, such as developing drugs, therapies, and lifestyle interventions to extend human health span.

The largest prize of $81 million will be awarded to researchers who can demonstrate methods to rejuvenate older adults by up to 20 years, with additional bonuses of $71 million for 15 years and $61 million for 10 years.

Participating teams are required to submit abstracts of existing therapeutic studies, including data from cell, animal, and human research. Landmark studies that fulfill the XPRIZE Foundation’s criteria for safety, feasibility, and effectiveness will be shortlisted as semi-finalists, and relevant studies may advance to the clinical trial stage in 2026.

However, the XPRIZE Foundation has not yet defined specific criteria for evaluating improvements in health lifespan. It plans to collaborate with an independent expert advisory committee to identify and validate new biomarkers and other indicators of aging. Rather than focusing solely on age-related diseases, the foundation aims to understand the broader impact of the findings.

Peter Diamandis, the founder and executive chairman of XPRIZE, believes that the breakthroughs from this competition will contribute to the prevention of chronic diseases associated with aging, which can strain healthcare systems.